Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications
|
|
- Millicent Barker
- 5 years ago
- Views:
Transcription
1 Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Current Classification of Psychotropic Medications The Official Nomenclature Why it Does Not Work Why we need a Neuroscience-guided System Proposed International Neuroscience-Based Nomenclature () Description Review and Discussion An Alternative Simpler Mechanistic Classification and its Clinical Application Description Clinical Application Why Nomenclature Matters Organization of information about available medications Synthesis of current knowledge and incorporation of new information Enables practice of Evidence-Based Medicine Framework to better inform pharmacologic treatment decisions What Clinicians Need and Want in a Pharma Nomenclature System that optimally guides informed choices about initial treatment and next pharmacologic step/s for a range of psychiatric conditions Based on contemporary scientific knowledge Allows easy incorporation of new information Provides language for communication about pharmacologic treatment with clinicians and patients Does not conflict with the way medications are used Comprehensive and also Comprehensible Coherent Simple Easy to use Current Nomenclature of Psychotropic Medications (~170 used) The official taxonomy of psychiatric medications (WHO) (ATC CLASSIFICATION SYSTEM AS WITH ALL OTHER MEDICATIONS) The WHO Classification of PSYCHOTROPICS NO5 and NO6 Agents that alter function of the mind What is the classification that clinicians use? Why current terminology is past breaking point!!! What we can learn from the approach taken by other medical disciplines? NO5 Psycholeptics Have a calming effect NO6 Psychoanaleptics Have a stimulating effect ATC = Anatomical Therapeutic Chemical; WHO = World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment Oslo, Accessed August 3, WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment Oslo, Accessed August 3, 2017.
2 The WHO Classification of PSYCHOLEPTICS NO5 The WHO Classification of PSYCHOANALEPTICS NO6 A. Major tranquilizers. Includes tetrabenazine, reserpine, cannabidiol, pimavanserin B. Anxiolytics Minor Tranquilizers Includes opioids, benzodiazepines, nonbenzodiazepines, barbiturates, gabapentin C. Hypnotics/Sedatives Includes GABA A agonists, GABA B agonists, H 1 antagonists, 5-HT 2A antagonists, melatonin, orexin WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment Oslo, Accessed August 3, A. Antidepressants B. Stimulants and Nootropics D. Anti-Dementia Drugs C. Psycholeptics & Psychoanaleptics in combination WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment Oslo, Accessed August 3, The WHO Classification of ANTIDEPRESSANTS NO6A A. Non-selective E. Others Monoamine Reuptake Inhibitors D. Selective Monoamine Oxidase A Inhibitors B. Selective Serotonin Reuptake Inhibitors C. Non-selective Monoamine Oxidase Inhibitors WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment Oslo, Accessed August 3, Problems with Current WHO Nomenclature Overly complex and yet uninformative Incomplete Indications neither specific to nor exclusive to medication Confusing Misleading to patients Have become less coherent as new medications cannot be easily classified Creative use of language (SGA, SNRI, SSRI) Contribute to stigma SGA = second-generation antipsychotic; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor. What Clinicians Need and Want in a Pharma Nomenclature System that optimally guides informed choices about initial treatment and next pharmacologic step/s for a range of psychiatric conditions Based on contemporary scientific knowledge Allows easy incorporation of new information Provides language for communication about pharmacologic treatment with clinicians and patients Does not conflict with the way medications are used Comprehensive and also Comprehensible Coherent Simple Easy to use What Pharma Nomenclature Do Clinicians Currently Use? Emphasis on simplicity and coherence (FGAs and SGAs) Antidepressants (TCAs, SSRIs, SNRIs, MAOIs, Other) Mood Stabilizers (Lithium, Anticonvulsants) Stimulants Benzodiazepines Others FGA = first-generation antipsychotic; TCA = tricyclic antidepressant; MAOI = monoamine oxidase inhibitor.
3 Can We Learn from Other Medical Disciplines? Though simpler, the clinician system has all the other problems leading to Not useful in guiding pharmacologic treatment choices Highly variable practices Stigma, lack of coherence, confusion So what have the other disciplines done? No longer use the WHO ATC (anatomy, therapeutic application, chemical structure) classification Group medications on the basis of mechanism of action Thereby addressing many of the problems seen with the ATC method Moving to an To keep up with scientific advances and clinical reality, learning from other disciplines, we wish to move to a Neuroscience-based System Leading psychopharmacologic organizations embarked on a 4-year process () ECNP, ACNP, CINP, AsCNP, IUBCPharmacol Formulated a proposal and draft was reviewed and field-tested on the Internet 28 scientific journal editors (all psychopharmacology journals) have endorsed its use in their Journal 6 dimensions on which 108 of the approximately 150 psychotherapeutic medications are classified Dimension 1: (Pharmacologic Domains) - 11 Acetylcholine, Dopamine, GABA, Glutamate, Histamine, Ion channel, Lithium, Melatonin, Norepinephrine, Opioid, Serotonin Dimension 2: (Mode of action) - 10 Agonist, Partial agonist, Antagonist, Positive allosteric modulator (PAM), Reuptake inhibitor, Reuptake inhibitor and Releaser, Reuptake inhibitor and antagonist, ion channel blocker, enzyme inhibitor, enzyme modulator Dimension 3: (Approved Indications) vary across countries based on decisions of local regulatory bodies Dimension 4: (Efficacy and Side Effects) information from guidelines, additional indications Dimension 5: (Practical Notes) clinical knowledge filtered through the taskforce Dimension 6: (Neurobiology) preclinical and clinical All medications should be described in terms of all clinically relevant modes of action, listing them in a hierarchical manner 108 of the approximately 150 psychotherapeutic medications are classified All medications should be described in terms of all clinically relevant modes of action, listing them in a hierarchical manner (based on???) 108 of the approximately 150 psychotherapeutic medications are classified Examples Olanzapine Antagonist; D 2, 5-HT 2A ; same as iloperidone Risperidone Antagonist; D 2, 5-HT 2A, NE α 2 Quetiapine MM; Antagonist; D 2, 5-HT 2A ; Reuptake inhibitor (NE) Aripiprazole Partial Agonist; D 2, 5-HT 2A
4 Is the System an Advance? Do You Find it Helpful? Neuroscience-Based Experts from across world have developed it Will be required in several scientific publications New information will be communicated with this terminology Appears highly sophisticated Is the System an Advance? Do You Find it Helpful? Not clinician-friendly at all!!! Long, complicated descriptions even essays Overly complex and yet incomplete Requires clinician to have much more sophisticated pharmacologic knowledge Not completely informative (affinity, intrinsic activity, fast/slow dissociation) Mechanisms of action incompletely understood Confusing on what parameters do you decide relevant pharmacology and how do you construct a hierarchy Currently only applicable to adult psychiatry We Need a Better System What Can We Do NOW? What Do Clinicians Need to Make Optimal Use of Medications we have for the Conditions we see A syndromal diagnosis An understanding of the nature of the underlying brain disorder Mechanism of action of the drug Based on contemporary scientific knowledge Allow easy incorporation of new information Language for communication about pharmacologic treatment Does not conflict with the way medications are used As Comprehensive as possible BUT MUST BE COMPREHENSIBLE Not confusing or incoherent Simple and Easy to use Do We Know How Psychotherapeutic Medications Work? Grossly Simplified Based on Common Denominator Stimulants: Increase DA (and NE) : Block DA (D 2 ) receptors Antidepressants: Increase 5-HT and/or NE Anti-dementia: Increase ACh Benzodiazepines: Stimulate GABA Lithium + Anticonvulsants: Second messengers and ion channels (membrane stabilization) Classification of Psychotherapeutic Medications, Circa 2017 A. D 2 Antagonists and Partial Agonists G. Other Lithium H 1 Antagonists Melatonin agonists F. AChE inhibitors E. Catecholamine reuptake inhibitors and release B. Monoamine D. Voltage-gated Calcium and Reuptake Inhibitors, Sodium Ion Channel Blockers Agonists, and MAOIs C. GABA-enhancing Agents (PAMs BDZs) Prior to Antipsychotic Agents Conventional or Typical (First-Generation) Atypical (Second-Generation) s 1980s 1990s 2000s Chlorpromazine Haloperidol Fluphenazine Clozapine Thioridazine Loxapine Perphenazine Trifluoperazine Risperidone Thiothixene Olanzapine Molindone Quetiapine Pimozide Ziprasidone Aripiprazole Paliperidone Iloperidone Asenapine Lurasidone Brexpiprazole Cariprazine
5 Dopamine Neurotransmitter/Receptor Involvement in Psychotic Disorders DA is believed to play a large role in the pathogenesis of psychotic symptoms All antipsychotics today ACT at postsynaptic DA D 2 receptors DA pathways include Mesolimbic: Too MUCH DA positive symptoms Mesocortical: Too LITTLE DA negative, mood, and cognitive symptoms Nigrostriatal: Blocking DA results in EPS Tuberoinfundibular: Blocking DA results in hyperprolactinemia EPS = extrapyramidal symptoms. Stahl SM. Stahl s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Fourth Edition. New York: Cambridge University Press; Dopamine PRESYNAPTIC NEURON Synaptic Vesicle Dopamine Receptor (D2) POSTSYNAPTIC NEURON Why Avoidance of EPS is So Important!!! Fewer EPS Better cognition Fewer negative symptoms Obtaining antipsychotic effect without EPS Less depression Less tardive dyskinesia Less nonadherence Tandon R. Psychiatr Q. 2002;73(4): EPS: The Atypical Advantage EPS profiles differ among atypical agents Determined by combination of following attributes: 5-HT 2A /DA blockade Affinity for DA D 2 receptor and ease of dissociation from DA D 2 receptor Partial agonism at DA D 2 receptor Intrinsic anticholinergic activity Prior to Antipsychotic Agents Conventional or Typical (First-Generation) Atypical (Second-Generation) s 1980s 1990s 2000s Chlorpromazine Haloperidol Fluphenazine Clozapine Thioridazine Loxapine Perphenazine Trifluoperazine Risperidone Thiothixene Olanzapine Molindone Quetiapine Pimozide Ziprasidone Aripiprazole Paliperidone Iloperidone Asenapine Lurasidone Brexpiprazole Cariprazine Tandon R. Psychiatr Q. 2002;73(4): D 2 Antagonists and Partial Agonists Therapeutic Applications NOTES 1. Psychosis: All are equally effective with varying side effects, with clozapine being more effective in psychosis refractory to other agents. EPS avoidance is important 2. Depression Bipolar depression those with very low EPS potential quetiapine, lurasidone, clozapine MDD as adjunct High affinity agent 3. Mania All are equally effective 4. OCD as adjunct High affinity agent 5. Neurodevelopmental Disorder with agitation Very high affinity agent MDD = major depressive disorder; OCD = obsessive-compulsive disorder. A. Psychosis B. Depression C. Mania D. OCD E. Neurodevelopmental Disorder with agitation Monoamine Reuptake Inhibitors, Agonists, and MAOIs Therapeutic Applications NOTES A. Depression B. Anxiety C. OCD D. Chronic Pain and Fibromyalgia
6 Agents in Various Classes of Individual Agents within each class VARY in Pharmacokinetics Pharmacodynamics Drug-drug interactions Range of therapeutic applications Amount of available clinical data and experience Ease of use Pharmacologic Treatment of Any Disease Know the Disease that you are treating Nature: Clinical, Etio-Pathophysiology Treatment targets; Treatment goals Know the Treatments at your disposal What they do; How they compare; Costs Principles of Treatment Measurement-based; Targeted; Individualized THE BEST TREATMENT TODAY Measurement-Based, Individualized* You can t manage what you don t measure. Unknown Specific vulnerabilities and needs of patient interact with specific profile of antipsychotic agent in the context of illness course to determine: Optimal dosing strategy Best benefit-cost differential These are difficult to predict ahead of time Match individual needs/vulnerabilities to agent profile as best as possible at initial selection of antipsychotic Monitor (both benefits and side effects) on ongoing basis There is no best agent or group of agents for all *Example of Schizophrenia. Why Nomenclature Matters Organization of information about available medications Synthesis of current knowledge and incorporation of new information Enables practice of Evidence-Based Medicine Framework to better inform pharmacologic treatment decisions Reconciling and Clinician-Friendly Systems Clinician-friendly system described is useful for broad grouping of psychotherapeutic medications It only approximates current science: greatest common denominator Best balance between precision and applicability is most useful for characterization of individual agents Detailed description of profile and other relevant information Overly cumbersome for grouping of agents Use both together as above Both will need to be reviewed and updated with time
Introduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationPsychiatric Pharmacotherapy { Objectives. Overview 4/5/2016
Psychiatric Pharmacotherapy { Elizabeth Lake, PharmD PGY1 Pharmacy Practice Resident G.V. Sonny Montgomery VA Medical Center Objectives The purpose of this activity is to enable the nurse practitioner
More informationChapter 161 Antipsychotics
Chapter 161 Antipsychotics Episode Overview Extrapyramidal syndromes are a common complication of antipsychotic medications. First line treatment is benztropine or diphenhydramine. Lorazepam is used in
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationFinal Exam PSYC2022. Fall (1 point) True or False. The DSM-IV describes the symptoms of acute intoxication with cannabis.
Final Exam PSYC2022 Fall 1998 (2 points) Give 2 reasons why it is important for psychological disorders to be accurately diagnosed. (1 point) True or False. The DSM-IV describes the symptoms of acute intoxication
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationAntipsychotics. Neuroleptics/ Major Tranquilizers. Hiwa K. Saaed, PhD Pharmacology & Toxicology /5/18 1
Antipsychotics Neuroleptics/ Major Tranquilizers Hiwa K. Saaed, PhD Pharmacology & Toxicology hiwa.saaed@univsul.edu.iq 2018-2019 12/5/18 1 Learning objectives Pharmacy students should: be familiar with
More informationContemporary Psychiatric-Mental Health Nursing. Psychopharmacology. Psychopharmacology - continued. Chapter 7 The Science of Psychopharmacology
Contemporary Psychiatric-Mental Health Nursing Chapter 7 The Science of Psychopharmacology Psychopharmacology A primary treatment mode of psychiatric-mental health nursing care Psychopharmacology - continued
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationPSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX
A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationESSENTIAL PSYCHOPHARMACOLOGY, Neurobiology of Schizophrenia Carl Salzman MD Montreal
ESSENTIAL PSYCHOPHARMACOLOGY, 2011 Neurobiology of Schizophrenia Carl Salzman MD Montreal EVOLVING CONCEPTS OF SCHIZOPHRENIA Psychotic illness with delusions, hallucinations, thought disorder and deterioration;
More informationTreat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering
Robert M. Millay RN MSN Ed Professor, Napa Valley College Psychiatric Technician Programs Copyright 2015, 2011, 2007, 2003, 1999, 1995, 1991 by Mosby, an imprint of Elsevier Inc. Treat Schizophrenia Schizoaffective
More informationWESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS
WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and
More informationANTIPSYCHOTICS/ NEUROLEPTICS
Pharmacological Interventions Tutorial Antipsychotic medications First Generation (Typicals) Includes phenothiazines, thioxanthenes, butyrophenones ANTIPSYCHOTICS/ NEUROLEPTICS Second Generation (Atypicals)
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationAntipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients
Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSupplementary Online Content
Supplementary Online Content Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. Published online August 17, 2016.
More informationDrugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD
Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be
More informationAntipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed)
Antipsychotics Detect, Select, Effect (P.I.E.C.E.S. 6 th Ed) CLeAR Webinar February 14, 2014 Paula Diaz (Pharm) Carol Ward MD Carol Ward Tertiary Mental Health IHA Hillside Centre (Acute Tertiary Mental
More informationANTIPSYCHOTIC POLYPHARMACY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University
More information#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Schizophrenia and Cognition Jeffrey A. Lieberman, MD Columbia University College of Physicians and Surgeons New York State Psychiatric
More informationWhat Team Members Other Than Prescribers Need To Know About Antipsychotics
What Team Members Other Than Prescribers Need To Know About Antipsychotics The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State
More informationPHARMACOLOGY Vol. I - Neuropsychopharmacology - Mirjam A.F.M. Gerrits and Jan M. van Ree
NEUROPSYCHOPHARMACOLOGY Mirjam A.F.M. Gerrits and Jan M. van Ree Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
More informationA Primer on Psychotropic Medications. Michael Flaum, MD
The Iowa Mental Health System and Employment for Individuals with Psychiatric Conditions Iowa Vocational Rehabilitation Services Conference Des Moines, IA, September 18, 2006 A Primer on Psychotropic Medications
More informationProposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)
Proposed Changes to Existing Measure for HEDIS 1 2020: Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) NCQA seeks comments on proposed modifications to the HEDIS Health
More informationIndex. E Elderly and dementia, 2 Epilepsy, 59 Escitalopram, 51, 87 Estazolam, 101 Extrapyramidal symptoms (EPS), 18
A Abilify, 143 Absolute neutrophil count (ANC), 29 Acetylcholine (Ach), 14, 15 ACTivities of daily living and cognition (ACTION) study, 167 AD Anti-inflammatory Prevention Trial (ADAPT) study, 156 Adverse
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationBeyond the antidepressant label: Neuroscience-based Nomenclature
Beyond the antidepressant label: Neuroscience-based Nomenclature Pierre Blier, MD, Ph.D Professor, Psychiatry and Cellular & Molecular Medicine University of Ottawa Endowed Chair and Director Mood Disorders
More informationSponsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy
The Future of Antipsychotic Therapy (page 7 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry University of California, San Diego School of Medicine Honorary Visiting Senior
More informationAntipsychotic Use in the Elderly
Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationPsychopharmacology: A Comprehensive Review
Psychopharmacology: A Comprehensive Review 1) The association between a chemical compound and its biological activity, pioneered by Bovet and colleagues in the 1930s is known as a) Symbiosis b) Structure-activity
More informationCHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES?
CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES? C.A.W. Rijcken 1, T.B.M. Monster 1, J.R.B.J. Brouwers 1, L.T.W. de Jong van den Berg 1 1 Department of Social
More informationThe antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in
Antipsychotic Drugs The antipsychotic drugs (also called neuroleptics or major tranquilizers) are used primarily to treat schizophrenia, but they are also effective in other psychotic and manic states.
More informationMental illness A Broad Overview. Dr H Pathmanandam March 2017
Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate
More informationREXULTI (brexpiprazole) oral tablet
REXULTI (brexpiprazole) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationMolina Healthcare of Texas
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Ingrezza (Marketplace) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information,
More informationUniversity of Groningen. Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia
University of Groningen Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to
More informationΝευροφυσιολογία και Αισθήσεις
Biomedical Imaging & Applied Optics University of Cyprus Νευροφυσιολογία και Αισθήσεις Διάλεξη 19 Ψυχασθένειες (Mental Illness) Introduction Neurology Branch of medicine concerned with the diagnosis and
More informationLooking to the Horizon: Novel Agents in Development for the Treatment of Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Looking to the Horizon: Novel Agents in Development for the Treatment of Depression Learning Objectives Explain the neurobiological
More informationObjectives. Mental Health Info MEDICATION USE IN ASSISTED LIVING FACILITIES FOR MENTAL HEALTH ISSUES 11/12/2018
MEDICATION USE IN ASSISTED LIVING FACILITIES FOR MENTAL HEALTH ISSUES Holly Altenberger, PharmD, RPh Director of Pharmacy O Connell Pharmacy holly@oconnellpharmacy.com Objectives At the conclusion of the
More informationStudy Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
More informationStudy Guide Unit 3 Psych 2022, Fall 2003
Psychological Disorders: General Study Guide Unit 3 Psych 2022, Fall 2003 1. What are psychological disorders? 2. What was the main treatment for some psychological disorders prior to the 1950 s? 3. What
More informationSP.236 / ESG.SP236 Exploring Pharmacology Spring 2009
MIT OpenCourseWare http://ocw.mit.edu SP.236 / ESG.SP236 Exploring Pharmacology Spring 2009 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. Atypical (2
More information11/10/16. Neurotransmitters and their Receptors. Professor Abercrombie, Chapter 6, Neuroscience, 4 th ed, D. Purves et el.
Chapter 6, Neuroscience, 4 th ed, D. Purves et el. Neurotransmitters and their Receptors Professor Abercrombie, 2016 Events from neurotransmitter release to postsynaptic excitation or inhibition Sequence
More informationExtrapyramidal Symptoms Associated with Antipsychotic Use
Extrapyramidal Symptoms Associated with Antipsychotic Use Tamara Pringsheim, MD, FRCPC, FAAN Associate Professor, University of Calgary Department of Clinical Neurosciences, Psychiatry, Pediatrics and
More information2. OVERVIEW... 1 The Focus of These Guidelines... 1 These Guidelines: What is Not Covered... 2
TABLE OF CONTENTS 1. PURPOSE... 1 2. OVERVIEW... 1 The Focus of These Guidelines... 1 These Guidelines: What is Not Covered... 2 3. EVALUATION... 2 TABLE 1. Laboratory Studies for Evaluating Psychotic
More informationGUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS
City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE
More informationAntipsychotic Medication
Antipsychotic Medication Mary Knutson, RN 3-7-12 Mosby items and derived items 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 1 Clinical Uses of Antipsychotics Short-term: in severe depression and
More informationFlorida Best Practice Medication Guidelines Principles of Practice for Adults
http://flmedicaidbh.fmhi.usf.edu Florida Best Practice Medication Guidelines Principles of Practice for Adults 1. Goal of the Guidelines Persistent gaps exist in the quality of mental health care delivered
More informationPHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS
PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS Yogesh Dwivedi, Ph.D. Assistant Professor of Psychiatry and Pharmacology Psychiatric Institute Department of Psychiatry
More informationKelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationKey concepts in psychopharmacology
Key concepts in psychopharmacology David Nutt Anne Lingford-Hughes Agonists, antagonists and partial agonists and antagonists at dopamine D 2 receptors Full agonist: dopamine, apomorphine Abstract Drugs
More informationSlide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts
Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder 0.5-2 mg /day
More information6/20/2014. Overview. Learning Objectives. Review of Schizophrenia. Diagnosis (DSM 5) Disclosure
Overview Diagnosis and proposed pathophysiology of schizophrenia Rating scales used in schizophrenia Madness and Confusion of Mind: Schizophrenia Pharmacotherapy Dongmi Kim, PharmD, BCPS, BCPP CPFI Annual
More informationMadness and Confusion of Mind: Schizophrenia Pharmacotherapy. Dongmi Kim, PharmD, BCPS, BCPP CPFI Annual Meeting 2014
Madness and Confusion of Mind: Schizophrenia Pharmacotherapy Dongmi Kim, PharmD, BCPS, BCPP CPFI Annual Meeting 2014 Learning Objectives 1. Apply the current evidence on the efficacy of pharmacologic and
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationFebruary 7-9, 2019 The Westin Fort Lauderdale Florida. Provided by
February 7-9, 2019 The Westin Fort Lauderdale Florida Provided by Addressing Your Greatest Concerns in Schizophrenia Management: From Suicide to Relapse Prevention and the Role of LAIs John Lauriello,
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationTargets of Psychopharmacological Drug Action
Targets of Psychopharmacological Drug Action (page 33 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry University of California, San Diego School of Medicine Honorary
More informationSlide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics
Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationWhat's New in the World of Antipsychotics?
Handout for the Neuroscience Education Institute (NEI) online activity: What's New in the World of Antipsychotics? (page 7 in syllabus) Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry
More informationSafe and Effective Use of. Psychotropic Drugs. Introduction. Psychotropic Drugs. Jun NAKAMURA
Psychotropic Drugs Safe and Effective Use of Psychotropic Drugs JMAJ 47(6): 259 264, 2004 Jun NAKAMURA Professor, Department of Psychiatry, School of Medicine, University of Occupational and Environmental
More informationPsychotropic Drugs 0, 4-
0, 4- } -v Psychotropic Drugs NORMAN L. KELTNER, Ed D, RN Associate Professor, Graduate Program, University of Alabama School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama DAVID
More informationLURASIDONE. THERAPEUTICS Brands LATUDA see index for additional brand names
LURASIDONE THERAPEUTICS Brands LATUDA see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: dopamine, serotonin receptor antagonist (DS-RAn) Atypical antipsychotic (serotonin-dopamine
More informationRiding the Waves: Tools for the Management of Bipolar Disorder
Riding the Waves: Tools for the Management of Bipolar Disorder Jacintha S. Cauffield, Pharm.D., BCPS, CDE Associate Professor of Pharmacy Practice Palm Beach Atlantic University Lloyd L. Gregory School
More informationDrugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes
CNS Spectrums (2017), 22, 375 384. Cambridge University Press 2017 doi:10.1017/s1092852917000608 Drugs for psychosis and mood: unique actions at,, and dopamine receptor subtypes Stephen M. Stahl ISSUE:
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationDisclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015
49th Annual Meeting Psychiatry for the Non-Psychiatry Specialist Jacintha Cauffield, PharmD, BCPS, CDE Associate Professor of Pharmacy Practice Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University
More informationSchizophrenia & the Antipsychotics
splitting of mind (cognition/emotion) from reality 1% of population globally shamans or mentally ill Several subtypes: paranoid / catatonic / disorganized / undifferentiated / residual positive ( exaggerated)
More informationChapter Chapter Chapter Chapter Chapter Chapter Chapter Chapter 8 Chapter
CONTENTS Preface Chapter 1 Principles of Chemical Neurotransmission Chapter 2 Receptors and Enzymes as the Targets of Drug Action Chapter 3 Special Properties of Receptors Chapter 4 Chemical Neurotransmission
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationHEDIS BEHAVIORAL HEALTH RESOURCE GUIDE
HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE What is HEDIS? 3 HEDIS Reference Guide for Behavioral Health 4 Behavioral Health HEDIS Measures 13 WHAT IS HEDIS? HEDIS (Healthcare Effectiveness Data and Information
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationDSM-5 Criteria: Bipolar Disorders
DSM-5 Criteria: Bipolar Disorders Box 1. Bipolar I Disorder: For a diagnosis of bipolar I disorder, it is necessary to meet the following criteria for a manic episode. The manic episode may have been preceded
More informationPsychopathology: Biological Basis of Behavioral Disorders
1 6 Psychopathology: Biological Basis of Behavioral Disorders 16 Psychopathology: Biological Basis of Behavioral Disorders The Toll of Psychiatric Disorders Is Huge Schizophrenia is the major neurobiological
More informationOffice Management of Patients Living With Schizophrenia
Office Management of Patients Living With Schizophrenia Dr. Richardson O. Tachere, MD; MPH; M.A (Health Mgt.); FRCPC. Psychiatrist, CMHA, Kitchener. A Day in Psychiatry - 2017 Wednesday November 8 th,
More informationFirst Steps: Considering Clozapine for your Patients
First Steps: Considering Clozapine for your Patients The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationPsychobiology Handout
Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are
More information^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs
^ PRIMER OF DRUG ACTION A comprehensive gyide to the actions, uses, and side effects of psychoactive drugs wm, ROBERT M.JULIEN M.D.. PH.D. Claire D. Advokat, Ph.D. Louisiana State University and Joseph
More information2015 Update on Psychotropics
2015 Update on Psychotropics Jeffrey T. Apter, M.D. August 2015 Princeton Medical Institute 256 Bunn Drive, Suite 6, Princeton NJ (609) 921-6050 Learning Objectives Upon completion of this session, participants
More informationPsychopharmacologic Updates. Nimisha Gokaldas, MD Medical Director Multnomah County, Mental Health and Addiction Services Division
Psychopharmacologic Updates Nimisha Gokaldas, MD Medical Director Multnomah County, Mental Health and Addiction Services Division This author has NO affiliations with or involvement in any organization
More informationAntidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych
Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych A. Heterocyclic antidepressants: (tricyclic and tetracyclic ), e.g.amitryptaline,imipramine. B. Monoamine oxidase inhibitors(m.a.o.i), e.g.phenelzine.
More information